Literature DB >> 29891672

HoxB13 mediates AR-V7 activity in prostate cancer.

Héctor I Navarro1, Andrew S Goldstein2,3,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29891672      PMCID： PMC6042116          DOI： 10.1073/pnas.1808196115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  7 in total

Review 1.  CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.

Authors:  Diogo A Bastos; Emmanuel S Antonarakis
Journal:  Expert Rev Mol Diagn       Date:  2018-01-16       Impact factor: 5.225

2.  Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.

Authors:  Zhong Chen; Dayong Wu; Jennifer M Thomas-Ahner; Changxue Lu; Pei Zhao; Qingfu Zhang; Connor Geraghty; Pearlly S Yan; William Hankey; Benjamin Sunkel; Xiaolong Cheng; Emmanuel S Antonarakis; Qi-En Wang; Zhihua Liu; Tim H-M Huang; Victor X Jin; Steven K Clinton; Jun Luo; Jiaoti Huang; Qianben Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-29       Impact factor: 11.205

3.  Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.

Authors:  Manish Kohli; Yeung Ho; David W Hillman; Jamie L Van Etten; Christine Henzler; Rendong Yang; Jamie M Sperger; Yingming Li; Elizabeth Tseng; Ting Hon; Tyson Clark; Winston Tan; Rachel E Carlson; Liguo Wang; Hugues Sicotte; Ho Thai; Rafael Jimenez; Haojie Huang; Peter T Vedell; Bruce W Eckloff; Jorge F Quevedo; Henry C Pitot; Brian A Costello; Jin Jen; Eric D Wieben; Kevin A T Silverstein; Joshua M Lang; Liewei Wang; Scott M Dehm
Journal:  Clin Cancer Res       Date:  2017-05-04       Impact factor: 12.531

4.  TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.

Authors:  Michael D Nyquist; Yingming Li; Tae Hyun Hwang; Luke S Manlove; Robert L Vessella; Kevin A T Silverstein; Daniel F Voytas; Scott M Dehm
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

Review 5.  Prostate cancer screening.

Authors:  James Eastham
Journal:  Investig Clin Urol       Date:  2017-06-20

Review 6.  Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice.

Authors:  Atsushi Mizokami; Kouji Izumi; Hiroyuki Konaka; Yasuhide Kitagawa; Yoshifumi Kadono; Kazutaka Narimoto; Takahiro Nohara; Amit K Bahl; Mikio Namiki
Journal:  Asian J Androl       Date:  2017 Mar-Apr       Impact factor: 3.285

7.  Mortality Rate and Years of Life Lost Due to Prostate Cancer in Yazd Province, Iran: A 10-year study.

Authors:  Mojtaba Mirzaei; Mahboobehsadat Mirzadeh; Mohsen Mirzaei
Journal:  Sultan Qaboos Univ Med J       Date:  2018-01-10
  7 in total
  6 in total

1.  MEIS-mediated suppression of human prostate cancer growth and metastasis through HOXB13-dependent regulation of proteoglycans.

Authors:  Calvin VanOpstall; Srikanth Perike; Hannah Brechka; Marc Gillard; Sophia Lamperis; Baizhen Zhu; Ryan Brown; Raj Bhanvadia; Donald J Vander Griend
Journal:  Elife       Date:  2020-06-18       Impact factor: 8.140

2.  Tensor-Decomposition-Based Unsupervised Feature Extraction Applied to Prostate Cancer Multiomics Data.

Authors:  Y-H Taguchi; Turki Turki
Journal:  Genes (Basel)       Date:  2020-12-11       Impact factor: 4.096

Review 3.  Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer.

Authors:  Marzieh Ehsani; Faith Oluwakemi David; Aria Baniahmad
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

4.  HOXB13 and TFF3 can contribute to the prognostic stratification of prostate adenocarcinoma.

Authors:  Andrei Daniel Timofte; Simona Eliza Giuşcă; Ludmila Lozneanu; Mariana Bianca Manole; Iulian Prutianu; Bogdan Gafton; Andreea Rusu; Irina Draga Căruntu
Journal:  Rom J Morphol Embryol       Date:  2021 Jan-Mar       Impact factor: 1.033

5.  Urinary exosome-based androgen receptor-variant 7 detection in metastatic castration-resistant prostate cancer patients.

Authors:  Chao Wang; Xiang Liu; Hongyan Li; Libo Zhao; Guanyi Kong; Jing Chen; Zhi Li; Jianfei Qi; Ye Tian; Fengbo Zhang
Journal:  Transl Androl Urol       Date:  2022-02

Review 6.  Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo.

Authors:  Amani Yehya; Fatima Ghamlouche; Amin Zahwe; Yousef Zeid; Kevork Wakimian; Deborah Mukherji; Wassim Abou-Kheir
Journal:  Cancer Drug Resist       Date:  2022-06-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.